Immunomodulatory Second-Line Therapies for Immune Thrombocytopenia.

Immunomodulatory Second-Line Therapies for Immune Thrombocytopenia.
Hamostaseologie. 2019 Jun 05;:
Authors: Lambert MP
Abstract
Management of immune thrombocytopenia (ITP) is complex requiring communication between patients and caregivers to establish a mutual understanding of the impact of the patient's disease on quality of life, the current symptoms and risk of morbidity/mortality and the goals of therapy. The currently available second-line therapies for ITP provide potential for management of thrombocytopenia and bleeding symptoms with medical therapy or surgical intervention potentially offering long-term remission. All therapies are associated with potential side effects and necessary monitoring or modifications/risks and careful discussion of these is necessary to determine the optimal therapy for each patient. This review covers second-line therapies for ITP and discusses the currently available information on immunomodulatory second-line treatments for ITP.
PMID: 31167247 [PubMed - as supplied by publisher]

Source: Hamostaseologie - June 4, 2019 Category: Hematology Authors: Lambert MP Tags: Hamostaseologie Source Type: research